The adult human brain in preclinical drug development
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Neurodegenerative disorders are caused by the death and dysfunction of brain cells, but despite a huge worldwide effort, no neuroprotective treatments that slow cell death currently exist. The failure of translation from animal models to humans in the clinic is due to many factors including species differences, human brain complexity, age, patient variability and disease-specific phenotypes. Additional methods are therefore required to overcome these obstacles in neuroprotective drug development. Incorporating target validation using human brain-tissue microarray screening and direct human brain-cell testing at an early preclinical stage to isolate molecules that protect the human brain may be an effective strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tissue Cells Feel and Respond to the Stiffness of Their Substrate
Discher, D. E., Janmey, P., & Wang, Y.-L. (2005) · Science · doi:10.1126/science.1116995 · Cited by 6,382 · cited 1×
“These include the artificial conditions that are required to keep brain cells alive in vitro (for example, high serum levels); the substrates that they grow o”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Microglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 1×
“Microglia, the macrophage cells of the brain, are also likely to show marked heterogeneity, from neuroprotective to neurotoxic phenotype”
BackgroundNeuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397
Activation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314
Simard, A. R., Soulet, D., Gowing, G., Julien, J.-P., & Rivest, S. (2006) · Neuron · doi:10.1016/j.neuron.2006.01.022 · Cited by 1,265
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons
Nagai, M., Re, D. B., Nagata, T., Chalazonitis, A., Jessell, T. M., Wichterle, H., & Przedborski, S. (2007) · Nature Neuroscience · doi:10.1038/nn1876 · Cited by 1,220
Astrocytic complexity distinguishes the human brain
Oberheim, N. A., Wang, X., Goldman, S., & Nedergaard, M. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.08.004 · Cited by 739
Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial
Gordon, P. H., Moore, D. H., Miller, R. G., Florence, J. M., Verheijde, J. L., Doorish, C., Hilton, J. F., Spitalny, G. M., MacArthur, R. B., Mitsumoto, H., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70270-3 · Cited by 649
Cited by
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
The promise of organ and tissue preservation to transform medicine
Giwa, S., Lewis, J. K., Alvarez, L., Langer, R., Roth, A. E., Church, G. M., Markmann, J. F., Sachs, D. H., Chandraker, A., Wertheim, J. A., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3889 · Cited by 539
Modeling Patient-Derived Glioblastoma with Cerebral Organoids
Linkous, A., Balamatsias, D., Snuderl, M., Edwards, L., Miyaguchi, K., Milner, T., Reich, B., Cohen-Gould, L., Storaska, A., Nakayama, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.063 · Cited by 502
The Human Brain in a Dish: The Promise of iPSC-Derived Neurons
Dolmetsch, R., & Geschwind, D. H. (2011) · Cell · doi:10.1016/j.cell.2011.05.034 · Cited by 304
Smith, A. M., & Dragunow, M. (2014) · Trends in Neurosciences · doi:10.1016/j.tins.2013.12.001 · Cited by 256
Self-citationPU.1 regulates Alzheimer’s disease-associated genes in primary human microglia
Rustenhoven, J., Smith, A. M., Smyth, L. C., Jansson, D., Scotter, E. L., Swanson, M. E. V., Aalderink, M., Coppieters, N., Narayan, P., Handley, R., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0277-1 · Cited by 155
Self-citationThe transcription factor PU.1 is critical for viability and function of human brain microglia
Smith, A. M., Gibbons, H. M., Oldfield, R. L., Bergin, P. M., Mee, E. W., Faull, R. L. M., & Dragunow, M. (2013) · Glia · doi:10.1002/glia.22486 · Cited by 141
“The outstanding efficiency with which these primary adult human cells are transfected demonstrates their usefulness as a model system for investigating basic cell biology as well as for drug discovery (Dragunow, 2008).”
BackgroundSelf-citationSmith, A. M., Gibbons, H. M., Oldfield, R. L., Bergin, P. M., Mee, E. W., Curtis, M. A., Faull, R. L. M., & Dragunow, M. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-85 · Cited by 107
“Although most of the research on M-CSF and microglia has been carried out using rodent cells and models, it is becoming increasingly clear that there are important differences between rodent microglia and their human counterpart [33,34].”
ResultSelf-citationAn organotypic brain slice preparation from adult patients with temporal lobe epilepsy
Eugène, E., Cluzeaud, F., Cifuentes-Diaz, C., Fricker, D., Le Duigou, C., Clemenceau, S., Baulac, M., Poncer, J.-C., & Miles, R. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2014.07.009 · Cited by 101
Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
McArthur, R. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42
Isolation and culture of functional adult human neurons from neurosurgical brain specimens
Park, T. I.-H., Schweder, P., Lee, K., Dieriks, B. V., Jung, Y., Smyth, L., Rustenhoven, J., Mee, E., Heppner, P., Turner, C., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa171 · Cited by 28
“…culture dissociated primary human neurons in vitro from neurosurgical specimens (Kim et al. , 1979; Brewer et al. , 2001; Brewer and LeRoux, 2007; Dragunow, 2008; Rice, 2012; Zhang et al. , 2016; Spaethling et al. , 2017), but low yields and the complexity of the isolation procedure have limited…”
Self-citationSmith, A. M., Gibbons, H. M., Lill, C., Faull, R. L. M., & Dragunow, M. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-520-0_6 · Cited by 18
Self-citationHuman iPSC Models in Drug Discovery: Opportunities and Challenges
Silva, M. C., Cross, A., Brandon, N. J., & Haggarty, S. J. (2017) · Comprehensive Medicinal Chemistry III · doi:10.1016/b978-0-12-409547-2.12284-x · Cited by 6
Metadata
- Authors
- Dragunow, M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-07-11
- Volume
- 7
- Issue
- 8
- Pages
- 659-666
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2051205314
- Cited by
- 119
- References
- 12
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.